Starpharma Holdings Limited (SPL)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!

General Information
Company Name: Starpharma Holdings Limited
Stock Code: SPL
GICS Sub-Industry: Biotechnology
Market Cap ($M): 153
Equiv. Shares (M): 319

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.480 $ 0.500 $ 0.500 $ 0.475 $ 0.505 654,292 $ -0.025  -4.950 %

Current Broker Consensus Recommendation more
Recommendation: Buy (1.5)
Recommendation Date: 12th Nov 2014
Brokers Surveyed: 2

Company Overview

Business Description:
Starpharma Holdings Limited (SPL) is a biotechnology company that engages in the development of dendrimer products for pharmaceutical, life science and other applications. SPL's underlying technology is built around dendrimers, a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. SPL has three core development programs: VivaGel portfolio, drug delivery, and agrochemicals.

Strategy Analysis:
Starpharma Holdings reported a net loss of $1.83m for the half-year ended 31 December 2012. Revenues from ordinary activities were $1.29m, up 24% from last year. Basic and Diluted EPS was (1.0) cent compared to (2.0) cents last year. The net operating cash outflow was $10.24m compared to an outflow of $3.9m in the pcp. No dividend was declared.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016  F -- 0.4 -91.5 120.0 -- 0.0 --
2015  F -- 4.7 -- 10.2 -- 0.0 --
2014  A -14.6 -5.2 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Bionomics (BNO) $205 M -- 6.3117 0.3108 63.6364 8.7034 6.6396 0.00 0.00 0.00
CSL (CSL) $37,337 M 0.0899 0.2412 0.0806 27.5143 22.1683 20.5147 1.53 1.83 2.04
Mesoblast (MSB) $1,280 M -- -- -- -- -- -- 0.00 0.00 0.00
Starpharma (SPL) $161 M -- -- -0.9149 -- 10.7447 126.2500 0.00 0.00 0.00
Sirtex Medical (SRX) $1,475 M 0.2906 0.5155 0.3526 63.1961 41.7000 30.8292 0.54 0.66 1.06

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
SPL 2.24 -- 4.15 -- 480.0
Market 0.91 15.3 1.20 1.75 1.52
Sector 0.81 18.0 2.78 1.24 7.45

Name Position Start Date
Dr Jacinth (Jackie) Kincaid Fairley Chief Executive Officer,Executive Director 01 July 2006
Dr Peter J Jenkins Non-Executive Deputy Chairman,Non-Executive Director 13 May 1997
Ms Zita Peach Non-Executive Director 01 October 2011
Mr Peter R Turvey Non-Executive Director 19 March 2012
Mr Richard A Hazelton Non-Executive Director 01 December 2006
Mr Robert Bain Thomas Non-Executive Director,Non-Executive Chairman 04 December 2013

Name Position
N J Baade Chief Financial Officer
Nigel Baade Chief Financial Officer,Company Secretary
C P Barrett VP, Business Development
J R Paull VP, Development and Regulatory Affairs
D J Owen VP, Research

Substantial Shareholders
Holding Name
36,614,463 (12.90%) Acorn Capital Limited
14,406,827 (5.08%) The Dow Chemical Company
35,194,434 (12.40%) Allan Gray Australia Pty Ltd
34,174,302 (12.04%) M&G Investment Funds

Calendar of Events
Date Event
12 August 2015 Report (Annual)
12 August 2015 Report (Prelim)
23 February 2015 Report (Interim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Powers of Attorney

Handing over, what if you need someone else to make decisions for you? There are times in your life when you can't fulfil your financial obligations personally.

More details...


Australian Share Market - Close Up

CMC Markets 11/11/2014 | The Australian share market is in a decision zone - and trading from here may set the direction for the rest of the year.

Prices slashed - everything must go!

Nick Swales, Regional Director, Newcastle Office, Rathbones 27/10/2014 | “If you want to have a better performance than the crowd, you must do things differently from the crowd.” Sir John Templeton.

Aussie share market bulls now have company

Ric Spooner (Chief Market Analyst, CMC Markets) 20/10/2014 | Today, Australian investors will not have to go it alone buying stocks as they did for much of last week. Bargain hunters this morning will be supported by the morale boosting encouragement of a 3% turnaround in the German Dax and a 264 point rally in the Dow Jones.

The Importance of Ignoring the Noise of the Market

Carl Richards, director of investor education at the BAM Alliance 17/10/2014 | “As odd as it may sound, the sooner you start treating your investments like you treat life, the happier you’ll be with the outcome.”

You only dance twice

William H. Gross, Janus Capital Group 16/10/2014 | “Financial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding “minus” 10 basis points.”

The Big Picture - Australia 200 Index

CMC Markets 8/10/2014 | Share market indices around the globe are breaking down. While analysts cast around for reasons, it’s clear that a time factor is in play. Simply put, many investors “feel” a correction is overdue. How low could it go?


Sponsored Links